Drugs / MDC-CAR-BCMA001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05836896 | Feb 2024 → Jun 2027 expected | diffuse large B-cell lymphoma, plasma cell myeloma | Technical University Dresden | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDC-CAR-BCMA001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05836896 ↗ |
| Modality | Cell therapy | “BCMA directed CAR T-cells” NCT05836896 ↗ |
| Route | Intravenous | “administered intravenously” NCT05836896 ↗ |